Table 1.
List of Study Biologic and Nonbiologic DMARDs for the Treatment of Rheumatoid Arthritis
| Drug | Manufacturer | FDA approval date for RA | HCPCS code |
|---|---|---|---|
| Abatacept (Orencia) | Bristol-Myers Squibb | December 2005 | J1029 |
| Adalimumab (Humira) | AbbVie | December 2002 | J0135 |
| Anakinra (Kineret) | Sobi | November 2001 | J3490 |
| Certolizumab (Cimzia) | UCB | May 2009 | J0717 |
| Etanercept (Enbrel) | Amgen | November 1998 | J1438 |
| Golimumab (Simponi) | Janssen Biotech | April 2009 | J1602 |
| Infliximab (Remicade) | Janssen Biotech | November 1999 | J1745 |
| Rituximab (Rituxin) | Genentech | February 2006 | J9310 |
| Tocilizumab (Actemra) | Genentech | January 2010 | J3262 |
| Tofacitinib (Xeljanza) | Pfizer | November 2012 | NA |
a
Nonbiologic small-molecule DMARD.
DMARD indicates disease-modifying antirheumatic drug; HCPCS, Healthcare Common Procedure Coding System; NA, not applicable; RA, rheumatoid arthritis.